Inhibitors of these kinases are under consideration for treatment of immune disorders [27,28,29], and one inhibitor of JAK3, tofacitinib, is in clinical use for treatment of rheumatoid arthritis [30]. The gene discussed is JAK3; the disease is immune system disorder.